Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study to Explore the Clinical Efficacy of GS-7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant

NCT01559844 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01559844
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01559844 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study to Explore the Clinical Efficacy of GS-7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2012
Completion date
October 31, 2014
Enrollment
61 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, hepatocellular carcinoma